Silk Logistics Holdings (ASX:SLH) Announces ACCC Pauses Review Timeline
Silk Logistics Holdings (ASX:SLH) updates investors on ACCC pausing the review of its acquisition by DP World Australia, with the scheme meeting set for June 2025.
Tag: Regulatory News & Compliance
Osteopore Limited (ASX:OSX) Secures EU MDR Approval for Custom Implants
Osteopore (ASX:OSX) secures EU MDR approval for custom orthopaedic and cranial implants, expanding its market in Europe.
Dateline Resources Limited (ASX:DTR) Advances Colosseum Project with Mining Rights Confirmation
Dateline Resources (ASX:DTR) secures mining and rare earth exploration rights for its Colosseum Project, enhancing its growth prospects.
Cochlear Limited (ASX:COH) Responds to US Tariff Announcement
Cochlear Limited (ASX:COH) confirms it can continue duty-free imports of hearing implants despite new US tariffs.
Trigg Minerals Limited (ASX:TMG) Announces Antimony Exemption from US Tariffs
Trigg Minerals (ASX:TMG) secures antimony exemption from US tariffs, propelling the development of its Wild Cattle Creek project.
Abacus Group (ASX:ABG) Receives Acquisition Proposal for ASK
Abacus Group (ASX:ABG) receives unsolicited proposal from Ki Corporation and Public Storage to acquire additional ASK securities.
Dropsuite Limited (ASX:DSE) Declared Unacceptable Circumstances
Dropsuite Limited (ASX:DSE) has been declared to have unacceptable circumstances by the Takeovers Panel due to major shareholder Topline’s non-compliance.
Structural Monitoring Systems PLC (ASX:SMN) Updates on US Tariffs Impact
Structural Monitoring Systems PLC (ASX:SMN) announces an update on US reciprocal tariffs, confirming tariff-free status for its compliant avionics products and ongoing monitoring of trade impacts.
Mesoblast (ASX:MSB) Announces U.S. Tariff Exemption for Allogeneic Cell Therapies
Mesoblast (ASX:MSB) announces its allogeneic cell therapies are exempt from U.S. tariffs as ‘U.S. Country of Origin’ products.
Orthocell Limited (ASX:OCC) Receives FDA Clearance for Remplir™
Orthocell (ASX:OCC) secures FDA clearance for Remplir™, enabling entry into the US $1.6 billion nerve repair market.